Blood protein test identifies Alzheimer’s-linked gene variant
Compared with DNA tests, blood protein measurements scored 0.977 in one cohort and 1.000 in three others for separating variant carriers from non-carriers.
Independent replication
In people from four cohorts, this observational study compared blood levels of APOE4, a form of a fat-carrying protein, with DNA tests for the corresponding Alzheimer’s risk variant. Researchers set blood-test thresholds in one cohort and checked them in the other three.
The scores measure how well a test separates carriers from non-carriers; 1.000 indicates perfect separation. The blood test also distinguished people with one copy of the variant from those with two. Carrier status identified by either method showed similar associations with testing positive for amyloid, a protein linked to Alzheimer’s disease. Both methods also showed similar links to higher dementia-severity ratings and worsening ratings over time.
Why it matters
Alzheimer’s disease is an age-related disorder influenced by genetics. The study addresses whether blood protein measurements could offer a scalable alternative to DNA testing for assessing inherited risk and prognosis.
Caveats
This observational study assessed variant classification and disease-related associations, not whether using the test improves care. The findings are from a preprint that has not been peer-reviewed.
The paper
Clinical utility of plasma APOE proteotyping for Alzheimer's disease risk and prognosis
University of Pittsburgh
medRxiv, 11 Oct 2026, CC BY, Preprint, not peer-reviewed
